Chapter 11: Challenges in and principles for conducting systematic reviews of genetic tests used as predictive indicators

Journal of General Internal Medicine

Volumn 27, Issue SUPPL.1, 2012, Pages

  Jonas, Daniel E ^a   Wilt, Timothy J ^b,c   Taylor, Brent C ^b,c   Wilkins, Tania M ^d   Matchar, David B ^e,f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

genetic test; predictive tests; prognostic tests; risk; systematic review methods

Indexed keywords

CANCER GENETICS; CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE SEVERITY; DNA DETERMINATION; DNA EXTRACTION; ENVIRONMENTAL FACTOR; ETHICS; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; PENETRANCE; PLEIOTROPY; PREDICTIVE VALUE; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW (TOPIC); TIME; TREATMENT RESPONSE; VALIDITY;

DATABASES, BIBLIOGRAPHIC; EVIDENCE-BASED MEDICINE; GENETIC TESTING; GUIDELINES AS TOPIC; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVIEW LITERATURE AS TOPIC; RISK ASSESSMENT;

EID: 84862663715     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-011-1898-z     Document Type: Review

References (47)

1. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med. 2008.
2. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ Publication No. 10(11)-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality; March 2011; Available at: www.effectivehealthcare.ahrq. gov. Accessed August 22, 2011.
3. Lister Hill National Center for Biomedical Communications: Collections of the National Library of Medicine. What are reduced penetrance and variable expressivity? [electronic resource]; 2008; Available at: http://ghr.nlm.nih.gov/ handbook/inheritance/penetranceexpressivity. Accessed August 22, 2011.
4. HD Nelson LH Huffman R Fu EL Harris 2005 Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force Ann Intern Med 143 5 362 379 16144895 1:CAS:528:DC%2BD2MXhtVKgs7nJ
5. EP Whitlock BA Garlitz EL Harris TL Beil PR Smith 2006 Screening for hereditary hemochromatosis: a systematic review for the U.S. Preventive Services Task Force Ann Intern Med 145 3 209 223 16880463
6. National Office of Public Health Genomics C. ACCE Model Process for Evaluating Genetic Tests. 2007; Available at: http://www.cdc.gov/genomics/ gtesting/ACCE/index.htm. Accessed August 22, 2011.
7. RP Harris M Helfand SH Woolf, et al. 2001 Current methods of the US Preventive Services Task Force: a review of the process Am J Prev Med 20 3 Suppl 21 35 11306229 10.1016/S0749-3797(01)00261-6 1:STN:280:DC%2BD38%2FgvVWquw%3D%3D
8. Task Force on Genetic Testing (NIH). Promoting Safe and Effective Genetic Testing in the United States. Final Report of the Task Force on Genetic Testing. 1997; Available at: http://www.genome.gov/10001733. Accessed August 22, 2011.
9. MJ Khoury JS Dorman 1998 The Human Genome Epidemiology Network Am J Epidemiol 148 1 1 3 9663396 10.1093/aje/148.1.1 1:STN:280:DyaK1czis1Ghuw%3D%3D
10. GE Palomaki LA Bradley CS Richards JE Haddow 2003 Analytic validity of cystic fibrosis testing: a preliminary estimate Genet Med 5 1 15 20 12544471 10.1097/00125817-200301000-00003
11. GE Palomaki JE Haddow LA Bradley SC FitzSimmons 2002 Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians Genet Med 4 2 90 94 11882786 10.1097/00125817-200203000-00007
12. GE Palomaki JE Haddow LA Bradley CS Richards TT Stenzel WW Grody 2003 Estimated analytic validity of HFE C282Y mutation testing in population screening: the potential value of confirmatory testing Genet Med 5 6 440 443 14614395 10.1097/01.GIM.0000096500.66084.85
13. Sun F, Bruening W, Erinoff E, Schoelles KM. Evaluation Frameworks, Analytic Validity and Quality Rating of Genetic Tests. Evidence Report/Technology Assessment (Prepared by the ECRI Institute Evidence-based Practice Center under Contract No. HHSA 290-2007-10063-I.) AHRQ Pre-publication version. Rockville, MD: Agency for Healthcare Research and Quality; April 2001.
14. Agency for Healthcare Research and Quality. Genetic Tests for Cancer. Technology Assessment. Rockville, MD: Agency for Healthcare Research and Quality; 2006; Available at: http://archive.ahrq.gov/clinic/ta/gentests/. Accessed August 22, 2011.
15. W Burke D Atkins M Gwinn, et al. 2002 Genetic test evaluation: information needs of clinicians, policy makers, and the public Am J Epidemiol 156 4 311 318 12181100 10.1093/aje/kwf055
16. J Little L Bradley MS Bray, et al. 2002 Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations Am J Epidemiol 156 4 300 310 12181099
17. N Brockton J Little L Sharp SC Cotton 2000 N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review Am J Epidemiol 151 9 846 861 10791558 10.1093/oxfordjournals.aje.a010289 1:STN:280:DC%2BD3c3ltVWqtQ%3D%3D
18. d'Errico A, Malats N, Vineis P, Boffetta P. Review of studies of selected metabolic polymorphisms and cancer. IARC scientific publications. 1999(148):323-93.
19. M Yang HC Hendrie KS Hall OS Oluwole ME Hodes A Sahota 1996 Improved procedure for eluting DNA from dried blood spots Clin Chem 42 7 1115 1116 8674202 1:CAS:528:DyaK28XktFWmtLw%3D
20. KB Gale AM Ford R Repp, et al. 1997 Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots Proceedings of the National Academy of Sciences of the United States of America 94 25 13950 13954 9391133 10.1073/pnas.94.25.13950 1:CAS:528:DyaK2sXotVensb0%3D
21. AH Walker D Najarian DL White JF Jaffe PA Kanetsky TR Rebbeck 1999 Collection of genomic DNA by buccal swabs for polymerase chain reaction-based biomarker assays Environ Health Perspect 107 7 517 520 10378997 10.1289/ehp.99107517 1:CAS:528:DyaK1MXltVSktLs%3D
22. LC Harty PG Shields DM Winn NE Caporaso RB Hayes 2000 Self-collection of oral epithelial cell DNA under instruction from epidemiologic interviewers Am J Epidemiol 151 2 199 205 10645823 10.1093/oxfordjournals.aje.a010188 1:STN:280:DC%2BD3c7gvVChsw%3D%3D
23. M Garcia-Closas KM Egan J Abruzzo, et al. 2001 Collection of genomic DNA from adults in epidemiological studies by buccal cytobrush and mouthwash Cancer Epidemiol Biomarkers Prev 10 6 687 696 11401920 1:CAS:528:DC%2BD3MXlt1SrtL8%3D
24. JE Hixson DT Vernier 1990 Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI J Lipid Res 31 3 545 548 2341813 1:CAS:528:DyaK3cXitlWqu7o%3D
25. VO Tobe SL Taylor DA Nickerson 1996 Single-well genotyping of diallelic sequence variations by a two-color ELISA-based oligonucleotide ligation assay Nucleic Acids Res 24 19 3728 3732 8871551 10.1093/nar/24.19.3728 1:CAS:528:DyaK28Xmt1ahu7g%3D
26. LG Lee CR Connell W Bloch 1993 Allelic discrimination by nick-translation PCR with fluorogenic probes Nucleic Acids Res 21 16 3761 3766 8367293 10.1093/nar/21.16.3761 1:CAS:528:DyaK3sXmtFymsrs%3D
27. ST Bogardus Jr J Concato AR Feinstein 1999 Clinical epidemiological quality in molecular genetic research: the need for methodological standards JAMA 281 20 1919 1926 10349896 10.1001/jama.281.20.1919
28. LD Botto Q Yang 2000 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review Am J Epidemiol. 151 9 862 877 10791559 10.1093/oxfordjournals.aje.a010290 1:STN:280:DC%2BD3c3ltVWqug%3D%3D
29. JS Dorman CH Bunker 2000 HLA-DQ locus of the human leukocyte antigen complex and type 1 diabetes mellitus: a HuGE review Epidemiol Rev 22 2 218 227 11218373 10.1093/oxfordjournals.epirev.a018034 1:STN:280:DC%2BD3M3gtl2rtw%3D%3D
30. SC Cotton L Sharp J Little N Brockton 2000 Glutathione S-transferase polymorphisms and colorectal cancer: a HuGE review Am J Epidemiol 151 1 7 32 10625170 10.1093/oxfordjournals.aje.a010124 1:STN:280:DC%2BD3c%2FovVGjug%3D%3D
31. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report; 2002 Dec 17. Report No.: 1524-4539 (Electronic).
32. H Schunkert A Gotz P Braund, et al. 2008 Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease Circulation 117 13 1675 1684 18362232 10.1161/CIRCULATIONAHA.107.730614
33. BF Gage C Eby PE Milligan GA Banet JR Duncan HL McLeod 2004 Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin Thromb Haemost 91 1 87 94 14691573 1:CAS:528:DC%2BD2cXosVWiuw%3D%3D
34. BF Gage LJ Lesko 2008 Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues J Thromb Thrombolysis 25 1 45 51 17906972 10.1007/s11239-007-0104-y 1:CAS:528:DC%2BD1cXisVKmsb0%3D
35. DE Jonas HL McLeod 2009 Genetic and clinical factors relating to warfarin dosing Trends Pharmacol Sci 30 7 375 386 19540002 10.1016/j.tips.2009.05.001 1:CAS:528:DC%2BD1MXotFClsrg%3D
36. J Attia JP Ioannidis A Thakkinstian, et al. 2009 How to use an article about genetic association: A: Background concepts JAMA 301 1 74 81 19126812 10.1001/jama.2008.901 1:CAS:528:DC%2BD1MXntVWgsg%3D%3D
37. J Attia JP Ioannidis A Thakkinstian, et al. 2009 How to use an article about genetic association: B: Are the results of the study valid? JAMA 301 2 191 197 19141767 10.1001/jama.2008.946 1:CAS:528:DC%2BD1MXnsFGmsA%3D%3D
38. JA Williams K Johnson J Paulauskis J Cook 2006 So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics J Clin Pharmacol 46 3 258 264 16490801 10.1177/0091270005283463 1:CAS:528:DC%2BD28Xitl2qsLc%3D
39. CJ Hoggart TG Clark M De Iorio JC Whittaker DJ Balding 2008 Genome-wide significance for dense SNP and resequencing data Genetic epidemiology. 32 2 179 185 18200594 10.1002/gepi.20292
40. MI McCarthy GR Abecasis LR Cardon, et al. 2008 Genome-wide association studies for complex traits: consensus, uncertainty and challenges Nature reviews. 9 5 356 369 18398418 10.1038/nrg2344 1:CAS:528:DC%2BD1cXkvVOhs7Y%3D
41. Y Benjamini D Drai G Elmer N Kafkafi I Golani 2001 Controlling the false discovery rate in behavior genetics research Behav Brain Res. 125 1-2 279 284 11682119 10.1016/S0166-4328(01)00297-2 1:STN:280:DC%2BD3MrnsVGisg%3D%3D
42. S Wacholder S Chanock M Garcia-Closas L El Ghormli N Rothman 2004 Assessing the probability that a positive report is false: an approach for molecular epidemiology studies J Natl Cancer Inst. 96 6 434 442 15026468 10.1093/jnci/djh075
43. A Ziegler IR Konig JR Thompson 2008 Biostatistical aspects of genome-wide association studies Biom J. 50 1 8 28 18217698 10.1002/bimj.200710398
44. Caporaso N. Selection of candidate genes for population studies. In: Vineis P, Malats N, Lang M, et al, editors. Metabolic polymorphisms and susceptibility to cancer. Lyon, France: IARC Monogr Eval Carcinog Risks Hum; 1999. p. 23-36.
45. Matchar DB, Thakur ME, Grossman I, et al. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evid Rep Technol Assess (Full Rep). 2007(146):1-77.
46. Seidenfeld J, Samson DJ, Rothenberg BM, Bonnell CJ, Ziegler KM, Aronson N. HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors/Technology Assessment No. 172. Rockville, MD: (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center, under Contract No. 290-02-0026.) 2008.
47. U.S. Preventive Services Task Force. Genetic risk assessment: recommendation statement. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005;143(5):355-61.